The prion diseases are unique in that they present as sporadic, inherited, and infectious disorders (Ridley et al. 1986; Prusiner 1989; Richardson and Masters 1995) . For many years, they were classified as slow virus infections (Sigurdsson 1954; Gajdusek 1977) . Although much em phasis was placed on the transmissible nature of the prion diseases for many decades, studies of the inherited aspects of these disorders are now well appreciated (for review, see Brown et al. 1991; Prusiner 1994; Gambetti et al. 1995) .
Nineteen different mutations of the prion protein (PrP) gene that result in non-conservative substitutions or in sertions have been identified in families with a history of inherited central nervous system (CNS) disease. Genetic linkage of a P102L mutation to Gerstmann-StrausslerScheinker disease (GSS) established that familial prion diseases are hereditary disorders and provided a novel mechanism to explain how the prion diseases could man ifest as both genetic and infectious illnesses (Hsiao et al. 1989; Prusiner 1989) . The discovery of a mutation at codon 102 in the PrP gene that is responsible for this dominantly inherited disease, permits unambiguous di-*Corresponding authot. agnosis during life as well as identification of individuals at risk.
In our initial attempt to model GSS in transgenic mice, we constructed a mutated cosmid clone contain ing the Prnp'' gene from the ILn/J mouse (Hsiao et al. 1990 ). The resulting clone encoded mouse PrP-A (MoPrP-A) with a substitution of leucine for proline at codon 101 designated PIOIL, which corresponds to codon 102 in human PrP (HuPrP). Two lines of these mice developed CNS dysfunction between 50 and 300 days of age. That overexpression of Syrian hamster (SHa) PrP and wild-type MoPrP-B can produce neurodegenera tion of the CNS as well as neuromyopathy (Westaway et al. 1994 ) forced us to re-examine neurodegeneration in Tg(MoPrP-PlOlL) mice (Hsiao et al. 1990 ). We con structed additional lines of Tg(MoPrP-PlOlL) mice as well as control lines of Tg(MoPrP-A) mice. Mice overex pressing wild-type MoPrP-A remained well for >600 days, in contrast to those overexpressing MoPrP-PlOlL, all of which become ill between 150 and 300 days of age.
The wide range in the age of onset of spontaneous illness in these Tg(MoPrP-PlOlL) mice contrasts with experimental scrapie, in which incubation times for a group of animals receiving the same inoculum are de novo genetation of prion infectivity always similar. We produced high-copy-number Tg(MoPrP-PlOlL) mice on a background in which the wild-type MoPrP gene had been ablated by gene targeting (Prnp°^°) (Biieler et al. 1992) . Prnp°^° mice, which do not express MoPrP, are resistant to mouse prions (Biieler et al. 1993; Prusiner et al. 1993; Manson et al. 1994; Sakaguchi et al. 1995) . The resulting Tg(MoPrP-PlOlL)-Pj.j^pO/0 ^^Q exhibited a remarkable uniformity in the timing of their onset of illness, a shorter mean duration of illness and neuropathologic changes characterized by numerous PrP plaques. Brain extracts prepared from spontaneously ill Tg(MoPrP-PlOlL) mice reproducibly transmitted CNS degeneration to low-copy-number Tg-(MoPrP-P101L)196 mice -350 days after intracerebral inoculation. Crossing of Tg(MoPrP-P101L)196 mice onto the null background shortened these incubation times to -200 days. Uninoculated Tgl96/FVB mice and Tgl96/ Pj.j^pO/0 j^^j,g ^^^ j^Q^ develop spontaneous CNS disease nor did Tgl96/FVB mice and Tgl96/Prnp°^" mice inoc ulated with brain extracts from healthy nontransgenic control littermates. Comparison of muscle and periph eral nerve from spontaneously ill Tg(MoPrP-PlOlL) mice, age-matched Tg(MoPrP-P101L)196 and aged Tg-(MoPrP-A) mice revealed that overexpression of MoPrP-PIOIL, but not wild-type MoPrP-A, resulted in patholog ical abnormalities in muscle and peripheral nerve in ad dition to neurodegeneration of the CNS. These results demonstrate that disease in Tg(MoPrP-PlOlL) mice is caused specifically by the adverse effects of mutant PrP rather than overexpression of PrP encoded by the transgene.
Results

Mutant and wild-type MoPiP transgenes
We constructed a series of Tg(MoPrP-PlOlL) mice using fertilized eggs from FVB mice. The resulting mice ex press transgene-derived mutant MoPrP-PlOlL and en dogenous wild-type MoPrP. The Tg(MoPrP-P101L)/FVB mice differ from Tg(MoPrP-P101L)87 and Tg(MoPrP-P101L)174 mice produced earlier using fertilized eggs from a (C57BLxSJL)F2 cross. In addition, the cosSHa.Tet vector used to construct the Tg(MoPrP-P101L)FVB mice differs from the ILn/J cosmid clone used in our initial studies (Hsiao et al. 1990 ).
Founder transgenic mice were generated by microin jection of linearized DNA from the cosSHa. Tet con structs, eight expressing MoPrP(PlOlL) designated Tg(MoPrP-P101L)/FVB and two expressing wild-type mouse PrP^-A designated Tg(MoPrP-A)/FVB. Three Tg(MoPrP-P101L)/FVB lines and one Tg(MoPrP-A)/FVB line were established. We estimated that levels of PrP*^ in the brains of mice from two lines expressing MoPrP-PIOIL, designated Tg(MoPrP-P101L)2247/FVB and Tg(MoPrP-P101L)2866/FVB, and one line expressing wild-type mouse PrP'^-A, designated Tg(MoPrP-A)4053/ FVB, were each about eightfold higher than PrP*^ levels in the brains of nontransgenic mice. The fourth line overexpressing MoPrP-PlOlL ~32-fold was designated Tg(MoPrP-P101L)2862/FVB.
Expression of MoPrP-PlOlL tiansgene produces CNS degeneration
Because wild-type and mutant MoPrP are overexpressed at equivalent levels in the brains of Tg(MoPrP-A)4053/ FVB, Tg(MoPrP-P101L)2866/FVB, andTg(MoPrP-PlOlL)-2247/FVB mice, we were able to assess the relative con tributions of the MoPrP(PlOlL) mutation and PrP overexpression upon the development of spontaneous neuro logic disease. In contrast to the Tg(MoPrP-A)4053/FVB mice, which remained free of CNS dysfunction for >600 days of age, the Tg(MoPrP-PI01L)2247/FVB and Tg(MoPrP-P101L)2862/FVB lines began to exhibit ataxia, rigidity, and lethargy between 150 and 200 days of age (Fig. 1) . By 300 days, 100% of Tg(MoPrP-P101L)2247/FVB mice had developed CNS dysfunction while -410 days was required for all of the Tg(MoPrP-P101L)2862/FVB mice to exhibit signs of CNS degeneration. The mean age of disease was 227 ±16 days (±S.E.M.) and 321 ± 21 days in 17 Tg(MoPrP-P101L)2247/FVB and 14 Tg(MoPrPP101L)2862/FVB mice, respectively (Table 1) . Nontransgenic littermates of the Tg{MoPrP-P101L)/FVB lines remained asymptomatic for >600 days.
The ages of onset of neurologic dysfunction in Tg(MoPrP-P101L)2866/FVB mice were indistinguishable from those in Tg(MoPrP-P101L)2247/FVB (Fig. lA, B) ; both of these Tg(MoPrP-PlOlL) lines overexpress the transgene about eightfold. The mean age of disease was 220 ± 10 days in 18 Tg(MoPrP-P101L)2866/FVB mice (Table 1) . Because Tg(MoPrP-A)4053/FVB, Tg(MoPrP-P101L)2247/FVB, and Tg(MoPrP-P101L)2866/FVB mice all express wild-type or mutant MoPrP*^ at the same lev els, we conclude that overexpression of PrP cannot ac count for the spontaneous development of neurologic symptoms in Tg(MoPrP-PlOlL) mice; rather, expression of MoPrP(PlOlL) is required for CNS disease in these transgenic mice.
The Tg(MoPrP-P101L)87 and Tg(MoPrP-P101L)174 mice were constructed with a modified ILn/J mouse cosmid (Hsiao et al. 1990; Hsiao et al. 1994) , whereas the Tg(MoPrP-P101L)2247/FVB and Tg(MoPrP-P101L)2866/ FVB mice were produced using cosSHa.Tet vector. An additional difference between the sets of transgenic lines is that the Tg(MoPrP-P101L)87 and Tg(MoPrP-P101L)174 mice were derived from outbred (C57BL/ 6xSJL)F2 fertilized oocytes, whereas the TgJMoPrP-P101L)2247/FVB and Tg(MoPrP-P101L)2866/FVB mice were derived from inbred FVB fertilized oocytes. Because all four transgenic lines display indistinguishable CNS degeneration, it is likely that the substitution of L for P at residue 101 is the only cause of the illness. Additional support comes from transgenic mice expressing chimeric mouse/human MHu2M PrP with the PIOIL mutation which also spontaneously develop CNS disease. Breed ing these Tg(MHu2M-P101L)69 mice to transgene ho mozygosity shortened the mean age of illness from 362 ± 13 (±s.E.M.) to 199 ± 2 days (Telling et al. 1995; G. Telling and S.B. Prusiner, unpubl.) .
The Tg(MoPrP-P101L)2862/FVB line that overexpresses mutant PrP -32-fold is of interest because we expected these mice to exhibit spontaneous illness at a younger age than the eightfold overexpressors; instead, they remained well up to 250 days of age, and a fev^ survived for more than 400 days (Fig. lA) . It is possible that the ~32-fold overexpression of PrP as measured by dot blot, overestimates the concentration of PrP^ that is correctly folded so as to render it eligible for conversion into PrP^^ Although the Tg(MoPrP-A)4053/FVB mice remained free of CNS dysfunction for >600 days of age, 6 of 20 mice developed CNS dysfunction between 605 and 815 days of age (Table 1) . At this late time, many animals were also dying of intercurrent illnesses which compli cated diagnosis. Apart from minimal spongiform alter ations in the white matter normally associated with ag ing in mice, no neuropathologic evidence for prion dis ease was evident. In addition, examination of brain extracts by Western blotting failed to detect the presence of protease-resistant PrP^'^. The absence of neuropatho logic features of prion disease in the brains of these mice reflects the difficulty of accurately diagnosing clinical prion disease in elderly animals.
Transgenic mice expressing similar levels of MoPrP with an E to K change at residue 199, equivalent to the E200K mutation in humans that produces inherited Creutzfeldt-Jakob disease (CJD), did not develop CNS ''Transgenic mice are designated according to the species of PrP expressed from the integrated transgene array. If mutant PrP constructs are expressed, the location of the mutated codon is indicated preceded by the single letter amino acid code of the wild-type codon followed by the mutant codon. Finally, the founder animal number from which the line was derived is used to distinguish individual lines. ''Protein expression relative to wild-type, nontransgenic mice. ''The number of mice spontaneously developing clinical signs of scrapie divided by the original number of mice is shown in paren theses.
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GENES & DEVELOPMENT (Table 1 ). The mean duration of illness, that is, the time from the appearance of clinical signs to death, was reduced by a factor of >5 from 17 ± 3 days in Tg-(MoPrP-P101L)2866/FVB mice to 3 ± 1 days in the Tg-(MoPrP-P101L)2866/Pmp°^° mice. Thus, expression of wild-type MoPrP*^, albeit at an eight-fold lower level than mutant MoPrP-PlOlL, profoundly affected the pro gression of disease in Tg(MoPrP-PlOlL) mice. When ad ditional groups of Tg(MoPrP-P101L)2866/Prnp°^° mice were observed more than a year after the initial studies described above were performed, the curves for ages of onset of illness in these mice were superimposable on that of the initial study and the mean ages for develop ment of neurologic disease were 149 ± 7 days (±S.E.M., n = 11) and 137 ± 3 days (n = 22) (Fig. IB) .
By mating Tg(MoPrP-P101L)2866/Prnp°/° mice to each other, we produced offspring that were homozygous for the MoPrP-PlOlL transgene array. These mice, des ignated Tg(MoPrP-P101L + ^ + )2866/Prnp°^°, had a mean age for the onset of neurologic disease of 85 ± 2 days (±s.E.M., n = 10) as well as an abbreviated clinical course ( 
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Tg(MoPrP-P101L)196 mice express the mutant MoPrP-PlOlL transgene at a low level and do not develop disease spontane ously . "Notations in parentheses indicate inoculum used in initial pas sage. ''Single digit following a hypen distinguishes individual mice from a particular line. ''One animal sick at 463 days. ■^One animal sick at 454 days. (Table 2C , E), indicating that only MoGSS and not wild-type Mo prions were generated in Tg(MoPrP-P101L)196/FVB mice inoculated with brain homogenates from spontaneously ill Tg(MoPrP-PlOlL) mice. These findings provide even more persuasive evi dence for de novo production of prions in mice express ing a transgene carrying the P102L mutation of GSS than that previously reported by two of us (S.B. Prusiner and S. J. DeArmond) .
Neuropathology of Tg(MoPrP-PlOlL) mice
Spongiform degeneration and reactive astrocytic gliosis were found in all mice expressing the PIOIL mutant transgene at the time they exhibited signs of CNS dys function ( Fig. 2A, B) . Like the Tg(MoPrP-P101L)174 and Tg(MoPrP-P101L)87 mice, occasional PrP plaques were detected in the brains of a few ill Tg(MoPrP-P101L)2866/ FVB and Tg(MoPrP-P101L)2247/FVB mice (Fig. 2D ). Un expectedly, the brains of all ill Tg(MoPrP-P101L)2866/ pj.j^pO/0 jjj^^g examined contained abundant PrP plaques that stained with PAS and a-PrP R073 antiserum (Fig.  2E) .
The most severe spongiform change and gliosis was found in the brains of spontaneously ill Tg(MoPrP-P101L)2862/FVB mice which overexpress mutant MoPrP^(PlOlL) -32-fold (Fig. 2C) . Vacuolation of the globus pallidus, cerebellum, and substantia nigra was ex tensive. Severe vacuolation of the neocortex and caudate was also found in these Tg(MoPrP-P101L)2862/FVB mice. The extreme vacuolation of cerebellar white mat ter in Tg(MoPrP-P101L)2862/FVB mice is unusual but shares some features with that reported for mice inocu lated with an extract prepared from a patient dying of GSS disease (Tateishi et al. 1979) . Like Tg(MoPrP-P101L)2866/Pmp°^° mice, Tg(MoPrP-P101L)2862/FVB mice contained abundant PrP plaques, although they were larger and more numerous (Fig. 2F) .
The neuropathology in Tg(MoPrP-P101L)196/Prnp°^° mice developing CNS degeneration after inoculation with homogenates prepared from spontaneously ill Tg(MoPrP-P101L)2247/FVB or Tg(MoPrP-P101L)2866/ FVB mice consisted of intense reactive astrocytic gliosis, particularly in the cerebellar cortex and along the corti cospinal tract (Fig. 2G, H) . Spongiform degeneration was most marked in the corticospinal tract reminiscent of the neuropathology found in humans who died of GSS. PrP amyloid plaques were found in the subcallosal region in two of three brains examined from Tg(MoPrP-P101L)196/Prnp°^° mice (Fig. 21) . No PrP plaques were seen in the brains of three ill Tg(MoPrP-P101L)196/FVB mice examined.
Immunoblots of brain extracts from Tg(MoPrP-P101L)Prnp"^" mice
The abundance of PrP amyloid plaques in the brains of ill Tg(MoPrP-P101L)2866/Prnp°^° mice (Fig. 2E) suggested that proteinase K-resistant PrP, that is PrP^'^, was likely to be demonstrable by Western immunoblotting. To the contrary, no PrP resistant to proteinase K digestion was detectable in extracts prepared from the brains of Tg(MoPrP-P101L)2866/Prnp°^° mice (Fig. 3) . From these results, we conclude that the PrP deposits in the brains of Tg(MoPrP-P101L)2866/Prnp°^° mice exhibiting clini cal signs of CNS dysfunction and the neuropathologic hallmarks of prion disease are not derived from proteaseresistant PrP^'^ molecules.
Unable to detect proteinase K-resistant PrP by immu noblotting of brain homogenates (Fig. 3) , we asked whether detergent-insoluble PrP isolated by ultracentrifugation after limited digestion with proteinase K might reveal protease-resistant PrP molecules. Thus, we exam ined fractions derived from the brains of spontaneously ill or inoculated Tg(MoPrP-PlOlL) mice and used as con trols the brains of Tg(MoPrP)4053/FVB mice overexpressing wild-type MoPrP and non-Tg(MoPrP-PlOlL) littermates, both of which were age-matched and well at the time of sacrifice. Both soluble and insoluble fractions were analyzed by immunoblotting after SDS-PAGE (Fig.  4) . Protease-resistant PrP was found almost exclusively in the detergent-insoluble fraction of each sample; minor amounts of protease-resistant PrP in the soluble fraction in some samples seem likely to be attributable to mixing during removal of the supematants. The molecular weight of the detergent-insoluble, protease-resistant PrP was similar to that of PrP^ at 33-35 kD, and thus, dif ferent from that of PrP 27-30 (Fig. 3) . We found no cor relation between the protease-resistant, insoluble PrP and the development of spontaneous CNS disease in Tg-(MoPrP-PlOlL) mice; furthermore, PrP molecules with 
Neuromyopathy in Tg(MoPrP-PlOlL) mice
Although we found no evidence of CNS degeneration in 6 of 20 Tg(MoPrP-A)4053/FVB mice dying between 605 and 815 days of age (Table 1) , we examined quadri ceps muscles from these aged mice, as well as clinically ill Tg(MoPrP-P101L)2866/FVB mice and age-matched Tg(MoPrP-P101L)196/FVB mice to ascertain whether overexpression of PrP in these transgenic mice caused peripheral neuropathy and myopathy similar to trans genic mice overexpressing SHa or MoPrP-B (Westaway et al. 1994) . Although there was no evidence for neuromyopathic changes in the skeletal muscle of aged TgiMoPrP-A)4053/FVB mice, the skeletal muscles of Tg-(MoPrP-P101L)87, Tg(MoPrP-P101L)174, and Tg(Mo-PrP-P101L)2866/FVB mice exhibited neuropathic and myo pathic changes concomitantly with the development of CNS disease at -200 days of age ( Fig. 5A-C) . Only very mild abnormalities of muscle and peripheral nerve were found in Tg(MoPrP-P101L)196/FVB mice sacrificed at the same age. Skeletal muscle from clinically ill Tg(MoPrP-P101L)2866/FVB mice revealed marked type I fiber pre dominance and grouping (dark muscle fibers in right two-thirds of the photomicrograph, Fig. 5A ) indicative of neurogenic rearrangement of muscle fiber types with a relatively normal distribution of type I and II muscle fibers in the left one-third. Occasional degenerating mus cle fibers were observed with rare fibers undergoing phagocytosis (Fig. 5B, arrow) . Muscle from age-matched Tg(MoPrP-P101L)196/FVB mice showed normal num bers and distribution of type I and II fibers, whereas the diameter of the type I fibers (darkly stained) appeared to be, on the average, about 10 |xm less than the diameter of type I fibers in normal mice (Fig. 5D ). Examination of (Table 3A) .
The brains of ill Tg(MoPrP-A)4053/FVB mice inocu lated with RML prions showed substantially reduced spongiform degeneration and reactive astrocytic gliosis compared to those of nontransgenic mice (Fig. 7) . Whether the shorter incubation time of Tg(MoPrPm B muscle from aged Tg(MoPrP-A)4053/FVB mice revealed no abnormalities in type I and II fiber size or distribution (Fig. 5E ). The NADH staining (Fig. 5C ) revealed subsarcolemmal accumulation of mitochondria, verified by the Gomori trichrome stain (ragged red fibers) and succinic dehydrogenase stain (latter two not shown), and abnor malities in the distribution of the sarcoplasmic reticu lum (motheaten fibers). Pathological changes in sciatic nerve were found in Tg(MoPrP-P101L)2866/FVB mice and included regional loss of axons and active Wallerian degeneration (Fig. 6) . The muscle fiber-type grouping ab normalities shown in Figure 5 is related to the axonal degeneration shown in Figure 6 . The degenerating fibers, mitochondrial hyperplasia, and motheaten fibers are my opathic features, and suggest that high expression of MoPrP-PlOlL, but not wild-type MoPrP, causes abnormali ties of skeletal muscle both directly and indirectly via peripheral nerve.
Abbreviated scrapie incubation times in Tg(MoPrP-A) mice
Studies with Tg(SHaPrP) mice demonstrated that the level of SHaPrP^ expression was inversely related to the length of the incubation time ). As expected, Tg(MoPrP-A)4053/FVB mice expressing high levels of MoPrP*^-A exhibited abbreviated incubation times of -45 days after inoculation with mouse RML prions (Table 3A) . The duration of illness was also short ened. Homogenates from two ill Tg(MoPrP-A)4053/FVB mice, designated RML(4053-1) and RML(4053-2) pro duced incubation times that were indistinguishable from those of RML prions passaged in CD-I Swiss mice or Tg(MoPrP-A)4053/FVB mice showing that passage 1 2 3 4 5 6 7 9 10 11 12 Figure 4 . The presence of detergent-insoluble, protease-resistant PrP in mouse brain does not correlate with disease in spon taneously ill or inoculated Tg(MoPrP-PlOlL) mice. Brain ho mogenates were adjusted to 100 | jLg total protein/ml in TNE (10 mM Tris at pH 8.0, 150 mM NaCl, 1 mM EDTA) containing 0.2% sarkosyl and proteinase K was added at a final concentration of either 10 M-g/ml [A] or 100 fxg/ml (B). Digestion was allowed to proceed for 1 hr at 37°C and was terminated by addition of 100 mM PMSF. Insoluble aggregates were pelleted by centrifugation at 100,000xg for 1 hr. Pellets from the high speed centrifugation were resuspended in cell lysis buffer containing 0.5% NP-40, 0.5% deoxycholic acid, 150 mM NaCl and 10 mM Tris-HCl, at pH 8.0 and added to an equal volume of 2x SDS-PAGE loading buffer. The supernatants following ultracentrifugation were concentrated by precipitation at -20°C in 5 vol of methanol followed by centrifugation at 3700xg for 15 min. Pellets from this low speed centrifugation were also resuspended in cell lysis buffer and added to an equal volume of 2x SDS-PAGE loading buffer. The samples were analyzed by SDS-PAGE and Western blotting using the a-PrP R073 antiserum. (Fig. 8) . Although the patterns of PrP^'^ deposition were similar in scrapied Tg-(MoPrP-A)4053/FVB and nontransgenic mice, histoblots showed lower levels of PrP^"^ in the brains of ill Tg(MoPrP-A)4053/FVB than in nontransgenic mice (data not shown).
Discussion
The development of a mouse model for human GSS (P102L) has substantially increased our understanding of the inherited prion diseases. Although we were initially concerned about the infrequency of PrP amyloid plaques, the lack of protease-resistant PrP, and transmission of disease to a minority of inoculated recipients with ex tremely prolonged incubation times (Hsiao et al. 1990 , each of those concerns has been addressed as de scribed here. From our results, we conclude that Tg(MoPrP-PlOlL) mice faithfully recapitulate virtually all fea tures of human GSS (P102L). Transgenic mice that overexpress wild-type MoPrP*" at the same level as mutant MoPrP'^(PlOlL) demonstrate clearly that the PIOIL mutation is required for CNS de generation. Our studies also demonstrate a profound suppressive influence of wild-type MoPrP*^ on both the clinical and neuropathologic features of the GSS phenotype. The inhibitory effects of wild-type MoPrP'^ were manifest in multiple ways: First, ablation of the wildtype MoPrP gene significantly modifies the clinical symptoms of spontaneously sick Tg(MoPrP-PlOlL) mice, changing the age of onset of CNS disease from a relatively stochastic process in Tg(MoPrP-P101L)FVB mice to a highly uniform process in Tg(MoPrP-PlOlL)-Prnp°^° mice (Fig. 1) . Second, expression of endogenous
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wild-type MoPrP caused the clinical phase of disease to be more protracted in Tg(MoPrP-PlOlL) mice. Third, elimination of endogenous wild-type MoPrP"^ expression modified the neuropathology of Tg(MoPrP-PlOlL) mice: Whereas relatively few PrP plaques could be detected in Tg(MoPrP-P101L)FVB mice, there was widespread depo sition of PrP amyloid plaques in Tg(MoPrP-PlOlL)-Pj.j^pO/0 j^j(,g ^^ addition to spongiform degeneration (Fig. 2) . Fourth, elimination of wild-type MoPrP*-expres sion rendered Tg(MoPrP-P101L)196 mice more suscepti ble to GSS prions from spontaneously sick Tg(MoPrP-PIOIL) mice, manifested by a -40% reduction of GSS prion incubation times in inoculated Tg(MoPrP-PlOlL)-196/Prnp°^° mice compared to Tg(MoPrP-P101L)196/ FVB recipients ( Table 2 ).
Transmission of de novo generated prions
The transmission experiments reported here demon strate unequivocally the formation of infectious prions in the brains of spontaneously ill Tg(MoPrP-PlOlL) mice and, in conjunction with many other lines of experimen tal investigation, continue to militate for the absence of a nucleic acid within the prion particle (Prusiner 1991; Prusiner 1982) . The reproducible transmission of neurodegeneration from Tg(MoPrP-PlOlL) mice and not from control nontransgenic mice (Table 2) (Table 2) , efficient transmission of mu tant PIOIL prions requires expression of MoPrP-PlOlL in these recipient mice. Prions produced de novo in Tg-(MoPrP-P101L)2247/FVB mice did not transmit disease to nontransgenic mice which only express wild-type Mo PrP or to Tg(MoPrP-A)4053/FVB mice which overexpress wild-type MoPrP and are highly sensitive to wildtype mouse prions.
Transgenetic studies argue that PrP'-' and PrP^^ form a complex during the conversion of PrP*^ into nascent Pj-psc Scott et al. 1993) . The data reported here underscore the results of human CJD and GSS prion transmissions in Tg(MHu2M)5378 and Tg{MHu2M-P102L)69 mice which argue that prion prop- The total concentrations of protein in 10% brain homogenates were determined by bicinchoninic acid assay. Aliquots of brain homogenates containing equal amounts of total protein in each case were either treated with 20 jxg of proteinase K for 60 min at 37°C (even-numbered lanes) or not treated (oddnumbered lanes). Samples were resolved by SDS-PAGE and an alyzed by Western blot. The blot was exposed to the a-PrP R073 antiserum, developed using enhanced chemiluminescence (ECL) and exposed to X-ray film. agation is facilitated by homology within the central do mains of HuPrP^ and HuPrP^*= (Telling et al. 1995) . Since wild-type MoPrP and MoPrP-PlOlL differ only at a single amino acid position, these results further demonstrate that prion propagation is facilitated by homology be tween PrP'^ and PrP^*" and that mismatch at residue 101 inhibits this process. This conclusion is strengthened by the results of serial passaging experiments which dem onstrate that prions produced de novo in the brains of Tg(MoPrP-PlOlL) mice discriminate between wild-type MoPrP^ and MoPrP^(PlOlL) expressed in Tg(MoPrP-P101L)196/FVB mice. In these transgenic mice, MoPrP-PIOIL prions, but not wild-type mouse prions, were pro duced as demonstrated by serial passage. Furthermore, expression of endogenous wild-type MoPrP^ in inocu lated Tg(MoPrP-P101L)196 mice had a potent inhibitory effect on the efficiency of MoPrP-PlOlL prion transmis sion.
Absence of protease-iesistant PrP in diseased Tg(MoPrP-PlOlL) mice
Although earlier studies had shown an excellent corre lation between the level of protease-resistant PrP^^ (McKinley et al. 1983 ) and scrapie prion infectivity, mak ing it a good marker for disease, we were unable to detect protease-resistant PrP^'' in these spontaneously ill mice or in inoculated Tg(MoPrP-P101L)196 mice. Whether ad ditional studies using lower concentrations of proteinase K for very brief periods of time (Lehmann and Harris 1996) will demonstrate a meaningful difference between mutant PrP from ill Tg(MoPrP-PlOlL) mice and controls such as uninoculated Tg(MoPrP-A) and Tg(MoPrP-P101L)196 mice remains to be determined. In earlier studies, we observed some protease-resistant PrP in brain extracts prepared from uninoculated Tg(SHaPrP) mice overexpressing SHaPrP when low concentrations of proteinase K were used for digestions . To differentiate what seems to be incompletely digested PrP*-^ from protease-resistant PrP^*^, we rou tinely used high concentrations of proteinase K. Since the mutant PrP(PlOlL) molecules clearly convey prion infectivity (Table 2) , we conclude in accord with earlier studies ) that the absence of proteaseresistant PrP^'' does not rule out prion disease, even though the presence of protease-resistant PrP^'^ is con sidered a diagnostic marker for the prion diseases .
The absence of detectable protease-resistant PrP^'' does not, however, preclude its presence in the infec tious prion. The sensitivity of the bioassay for prion de tection is several orders of magnitude greater than for the detection of PrP^'^. An alternative explanation for our inability to detect protease-resistant PrP^'^ in the brains of Tg(MoPrP-P101Lj mice is that the titer of infectious prions in ill Tg(MoPrP-PlOlL) mice is below the level for detection of protease-resistant PrP^'^. Experiments de signed to determine accurately the titer of prions in these mice by endpoint titration are underway and should resolve this issue. Such studies should also help determine whether infectivity generated in Tg(MoPrP-PIOIL) mice is resistant or sensitive to protease treat ment.
Similar to our Tg(MoPrP-P101L)2866/Prnp°^° mice (Fig. 2) , the brains of patients who die from GSS (P102L) always contain PrP amyloid plaques, yet detectable pro tease-resistant PrP is not a constant feature (Telling et al. 1995) . Although brain tissue from GSS (P102L) often transmits disease to inoculated recipients, this is also not a constant feature (Masters et al. 1981; Brown et al. 1994; Tateishi and Kitamoto 1995) . Whether all cases of GSS (P102L) will transmit disease to Tg(MHu2M-P102L) mice expressing a mutant, chimeric Hu/Mo PrP transgene remains to be established (Telling et al. 1995) . It is also of interest that the brains of patients who die of inherited CJD (E200K) have two forms of insoluble PrP; the mutant PrP is protease resistant, and the wild-type is sensitive to protease digestion (Gabizon et al. 1996 ). Yet, both the mutant and wild-type insoluble PrP can be dis tinguished from PrP*^ which is soluble in non-denaturing detergents.
The PIOIL mutation causes neurodegeneration and neuromyopathy
The fact that overexpression of wild-type PrP can pro duce neurodegeneration of the CNS as well as neuromy opathy (Westaway et al. 1994 ) prompted us to re-exam ine neurodegeneration in Tg(MoPrP-PlOlL) mice (Hsiao et al. 1990 ). The inclusion of additional control trans genic mice which overexpress wild-type MoPrP at levels equivalent to mutant PrP in Tg(MoPrP-PlOlL) mice demonstrates that the PIOIL mutation, not merely overexpression of PrP, causes the clinical and neuropathologic features of GSS. It is noteworthy that in addition to neurodegeneration of the CNS, skeletal muscle in high expressor Tg(MoPrP-PlOlL) lines developed severe neu ropathic and myopathic changes at the time they devel oped CNS disease (Fig. 5) . Features of amyotrophy with muscle fasiculations and fibrillations have been reported in an Italian kindred with GSS (PI02L) (Kretzschmar et al. 1992) , and the proband from a large English pedigree with GSS, in addition to neurogenic atrophy, showed muscle pathologic changes (Rosenthal et al. 1976) . Immunostaining studies have localized PrP at neuromus cular junctions in humans (Askanas et al. 1993 ) but mice deficient for PrP^ have been shown to exhibit normal electrical transmission at the neuromuscular junction (Brenner et al. 1992) . Whether neuromyopathic changes are an integral feature of human GSS (P102L) remains to be established.
Aged mice overexpressing either wild-type SHaPrP or the Prnp*" allele develop hind limb paresis as a result of a necrotizing myopathy and a demyelinating peripheral neuropathy (Westaway et al. 1994) . In contrast, aged mice overexpressing the Prnp"* allele showed no evidence of hind limb paresis or pathologic changes in skeletal muscle or peripheral nerves. The mechanism by which overexpression of mutant as well as foreign wild-type transgenes cause neuromyopathies is unknown. Perhaps, heterologous PrPs expressed in Prnp"* FVB mice tend to misfold more frequently than do homologous PrP mole cules. SHaPrP differs from MoPrP at 16 of 254 amino acid residues (Easier et al. 1986; Locht et al. 1986 ), MoPrP-B and Mo PrP-A differ at amino acid residues 108 and 189 (Westaway et al. 1987) , and MoPrP-PlOlL and MoPrP-A differ at a single residue.
Modifying the disease phenotypes of Tg(MoPrP-PlOlL) mice
Variations in the phenotypes of dominantly inherited neurologic diseases have often been attributed to the in terplay of gene products other than that which carries the disease-causing mutation. Two new mechanisms have been discovered recently, and a third is reported here. First, the triplet repeat diseases, such as myotonic dystrophy and Huntington's chorea, exhibit phenotypic variation with respect to the age of onset that depends upon the number of repeats (Fu et al. 1992; Huntington's Disease Collaborative Research Group 1993) . In general, there is an inverse relationship between the number of repeats and the age of onset; this finding provided a mo lecular basis for the phenomenon called anticipation. Second, the inherited prion diseases caused by a D178N mutation of the PrP gene present as dementing illnesses or insomnia, depending upon the polymorphic residue codon 129 (Goldfarb et al. 1992; Monari et al. 1994) . When VI29 is encoded on the mutant allele, patients present with a dementia; Ml29 presents as insomnia. Other PrP mutations at codons 102, 105, and 198 often present with ataxia (Dlouhy et al. 1992; Kitamoto et al. 1993) , while the codon 200 mutation seems to present invariably as a dementia (Gabizon et al. 1993) . Why a few members of a large pedigree with the codon 102 muta tion present with a dementia is unknown (Hsiao et al. 1989) .
The studies presented here show that the clinical and neuropathologic phenotypes of transgenic mice can be dramatically altered by ablation of the wild-type MoPrP gene. Tg(MoPrP-PlOlL) mice that harbor the wild-type MoPrP gene exhibit variable times of onset of neurologic disease ranging from 150 to 300 days followed by a clin ical phase of illness lasting almost three weeks (Fig. 1) .
The neuropathology of these mice shows spongiform de generation and relatively few PrP plaques. In contrast, >90% of Tg(MoPrP-P101L)/Prnp°^° mice develop clini cal signs of CNS dysfunction within a period of -21 days and have a short duration of illness lasting ~3 days. The neuropathology of these mice not only shows spongi form degeneration but also widespread deposition of PrP amyloid plaques (Fig. 2) . Crossing these mice to produce animals homozygous for the mutant transgene array pro duced spontaneous disease at -85 days of age (Fig. lA) . fust as expression of wild-type MoPrP dramatically al tered the clinical and neuropathologic phenotypes of Tg-(MoPrP-PlOlL) mice, expression of endogenous wildtype MoPrP in recipient Tg(MoPrP-P10IL)196 mice had a potent inhibitory effect on the efficiency of Mo prion transmission (Tab. 2).
Our results are consistent with a model in which mu tant and wild-type PrP*^ bind to an additional component required for prion propagation, which we have desig nated protein X (Telling et al. 1995) . Presumably, protein X facilitates the conversion of MoPrP*-(P101L) into PrP^". The elimination of wild-type MoPrP*^ expression converts the pathogenesis from what appears to be a sto chastic one in Tg(MoPrP-P101L)/FVB mice into a highly regulated process in Tg(MoPrP-P101L)/Prnp°^° mice. This change in prion disease pathogenesis is character ized by a narrowing of the range of ages at which neuro logic dysfunction is initially manifest and an abbreviated duration of illness. Mutant and wild-type MoPrP*^ differ only at one amino acid residue likely to lie outside the putative binding site for protein X, thought to reside at the carboxy-terminus of PrP*^ (Telling et al. 1995) . It re mains to be determined if the inhibitory effect of rela tively low levels of wild-type MoPrP*^ on inherited prion disease pathogenesis is a result of competition between mutant and wild-type MoPrP for binding to protein X.
Determinants of CNS pathogenesis in TgfMoPrP-PlOlL) mice
The numerous PrP amyloid plaques in the brains of Tg-(MoPrP-PI01L)2862/FVB and Tg(MoPrP-P101L)2866/ pj^pO/o jjjjQg jpjg 2) is particularly important since it clearly documents an abnormality in PrP structure and metabolism, despite the absence of demonstrable protease-resistant PrP^'' on Western blots (Fig. 3) . Demon-de novo generation of ption infectivity strating PrP^*^ in the brains of some patients, particularly those dying of inherited prion diseases, has also been problematic (Brown et al. 1986; Medori et al. 1992) .
The large numbers of PrP amyloid plaques in the brains of Tg(MoPrP-P101L)2862/FVB and Tg(MoPrP-P101L)2866/Prnp°^° mice suggest that mutant PrP^ is being refolded into molecules with substantial p-sheet content (Huang et al. 1996) . Although FTIR and CD spec troscopy have clearly demonstrated that a major confor mational change occurs during the conversion of wildtype PrP^ into PrP^^ (Pan et al. 1993) , no data on the secondary or tertiary structure of PrP(PlOlL) is yet avail able.
From data presented here, it appears that the number of PrP amyloid plaques may be directly proportional to the age of onset of neurologic dysfunction and to the ratio of mutant: wild-type MoPrP*^. Tg(MoPrP-P101L^^ + )2866/Prnp°^" mice homozygous for the PrP transgene array exhibit a reduced number of PrP amyloid plaques compared to mice that are hemizygous for the transgene array (data not shown) even though they presumably ex press twice as much MoPrP*^(P101L). These homozygous Tg(MoPrP-P101L + ^ + )2866/Prnp°^° mice develop CNS disease at -85 days of age compared to hemizygous mice that become ill at -145 days (Tab. 1). This finding argues that sufficient time must elapse for PrP amyloid deposi tion to occur. The hypothesis that age of onset of illness is a factor is supported by our finding that Tg(MoPrP-P101L)2862/FVB mice with numerous PrP amyloid plaques (Fig. 2) that express much higher levels of mu tant PrP^ and live longer than Tg(MoPrP-P101L)2866/ FVB mice. While the Tg(MoPrP-P101L)2862/FVB mice express ~32-fold more mutant MoPrP*^ than wild-type MoPrP*^, this high ratio of mutant wild-type MoPrP*-^ is similar to that in Tg(MoPrP-P101L)2866/Prnp°^° mice.
Whether factors other than the age of onset and the ratio of mutant to wild-type MoPrP^ influence patho genesis remains to be established. Why the Tg(MoPrP-P101L)2862/FVB mice exhibit such a late onset of dis ease (Fig. 1) is unclear, as they have the highest levels of expression of MoPrP*^(P101L) and the most severe dis ease neuropathologically with respect to spongiform de generation, astrocytic gliosis, and PrP amyloid deposi tion (Fig. 2) . It seems likely that either the measured ~32-fold overexpression of PrP overestimates the con centration of correctly folded PrP*^ that is eligible for conversion into PrP^"", or that insertion of the MoPrP-PIOIL transgene into the genome of the Tg(MoPrP-P101L)2862/FVB mouse alters the expression of a chromosomal gene that modulates the onset of illness. Because both the Tg(MoPrP-P101L)2247/FVB and Tg(MoPrP-P101L)2286/FVB lines of mice express lower levels of MoPrP'^(PlOlL) and develop signs of CNS dys function more rapidly, additional lines with high levels of MoPrP'^(PlOlL) need to be constructed in order to study this conundrum.
New approaches arising from these studies
The transmission of CNS degeneration from ill Tg(MoPrP-P101L)2247/FVB and Tg{MoPrP-P101L)2866/FVB mice to Tg(MoPrP-P101L)196/FVB and Tg(MoPrP-P101L)196/Prnp°^° mice and subsequent serial transmis sions not only provides convincing evidence for de novo generation of prions but also a new system for studies of genetic and infectious prion disease. The relatively short incubation times of -200 days in Tg(MoPrP-P101L)196/ Pj.jjpO/0 YTiice. inoculated with mutant prions (Table 1) make characterization of these prions produced de novo feasible for the first time.
Studies of the kinetics of plaque formation in Tg(MoPrP-P101L)2866/Prnp°''° mice are likely to give impor tant insights into the pathogenesis of the inherited hu man prion diseases. To our knowledge, this is the first animal model of a dominantly inherited neurologic dis ease in which the onset of illness is sufficiently uniform that animals sacrificed at different times in the study can be compared, as has been done in studies of rodents in oculated with scrapie prions. Tg(MoPrP-P101L)2866 and Tg(MoPrP-P101L)2247 mice may be useful models for evaluating gene therapy for the inherited human prion diseases. Mating Tg(MoPrP-P101L)2866 or Tg(MoPrP-P101L)2247 with Tg(MoPrP-A)4053 mice that overexpress wild-type PrP-A may prevent neurodegeneration or substantially delay the onset of disease. Alternatively, the uniformity of onset of clinical signs in Tg(MoPrP-P101L)2866/Prnp°^° mice may provide a testable model for evaluating pharmaceuticals that either stabilize PrP^ or inhibit the conversion of PrP*^ into PrP^'' (Cohen et al. 1994) . Thus, the transgenic mice described here may pro vide models for developing and evaluating effective treatments to prevent or ameliorate inherited neurode generative diseases.
Materials and methods
Production of transgenic mice
The MoPrP-A sequence used in this study was derived from C57BL mice (Locht et al. 1986; Westaway et al. 1987) . Construc tion of the MoPrP ORF cassette has been described previously (Rogers et al. 1991) . The construction of the MoPrP-PlOlL ex pression cassette containing a substitution of a leucine for pro line codon at residue 101 of the Mo PrP gene, corresponding to the GSS mutation at codon 102 of the human PrP gene, has been described (Hsiao et al. 1990 ). ORF cassettes were digested with Bglll which cleaves immediately adjacent to the initiation codon. The 5' protruding termini were filled in because of Klenow, and Sail linkers were added. Recombinant clones were cleaved with Sail and Xliol which cleaves immediately past the PrP termination codon, and purified ORF fragments were ligated to the Sail-cut cosSHa.Tet cosmid expression vector (Scott et al. 1992) . The isolation of recombinant cosmid clones was achieved by methods that have been described previously (Scott et al. 1993) . Notl fragments, recovered from large-scale DNA cosmid preparations, were used for microinjection into the pronuclei of fertilized FVB/N oocytes as previously de scribed (Scott et al. 1989) . Genomic DNA isolated from tail tissue of weanling animals was screened for the presence of incorporated transgenes using a probe that hybridizes to the 3'-untranslated region of the SHaPrP gene contained in the cosSHa.Tet vector (Scott et al. 1992 ).
Preparation of brain homogenates
Ten percent (wt/vol) homogenates of mouse brain were pre pared by repeated extrusion through an 18-gauge syringe needle followed by extrusion through a 22-gauge needle in phosphate buffered saline (PBS) lacking calcium and magnesium ions. For immunoblot analysis, samples were cleared of cell debris by a brief low-speed centrifugation.
Sources of prion inocula
The RML isolate from Swiss mice (Chandler 1961 ) was provided by Dr. William Hadlow (Rocky Mountain Laboratory, Hamil ton, Montana) and was passaged in Swiss mice from a closed colony at the Rocky Mountain Laboratory (Hamilton, MT) or in Swiss CD-I mice obtained from Charles River Laboratories (Wilmington, MA). For transmission of neurodegeneration from spontaneously sick Tg(MoPrP-PlOlL) mice, brain homogenates were prepared as described above.
Determination of incubation periods
Mice were inoculated intracerebrally with 30 |xl of brain extract using a 27-gauge needle inserted into the right parietal lobe, and observed for signs of disease. Additionally, uninoculated Tg(MoPrP-PlOlL) and Tg(MoPrP-A) mice were observed for spontaneous CNS disease. The preparation of inocula and cri teria for diagnosis of scrapie in mice have been described (Carl son et al. 1986 ). When clinical signs of CNS dysfunction ap peared, the mice were examined daily. To confirm the clinical diagnosis, the brains of some animals whose death was obvi ously imminent were taken for histopathological studies.
Immunoblotting
Total protein concentrations in brain homogenates were deter mined by bicinchoninic acid assay. Immuno dot blots for the determination of the relative levels of PrP expression in trans genic mouse brains were performed as described previously (Scott et al. 1993) . Samples for Western blot analyses were pre pared as described in the figure legends. Western blots were performed as described previously (Towbin et al. 1979; Barry and Prusiner 1986) , except that an enhanced chemiluminescent (ECL) detection method (Amersham, Arlington Heights, IL) was used. The blot was exposed to X-ray film. a-PrP rabbit R073 antiserum was used at a final dilution of 1:5000.
Immunohistochemistry
For immunohistochemistry, endogenous peroxidase activity was blocked with methanol-hydrogen peroxide (2 ml of 30% H2O2 in 200 ml methanol). To enhance PrP immunoreactivity, the sections were immersed in 1.3 mM HCl and autoclaved at 12rC for 10 min (Muramoto et al. 1992) . When the temperature decreased, the slides were placed under running tap water for 10 min followed by rinsing with TB (50 mM Tris-HCl at pH 7.6, with 150 mM NaClj. Nonspecific protein binding was blocked with TBS (25 mM Tris-HCl at pH 7.6, 0.05% Tween 20, 0.5 M NaCl, 5% nonfat milk) for 10 min. The a-PrP polyclonal rabbit R073 antiserum was diluted 1:250 in TBS. Tissue sections were incubated with the primary antiserum overnight at 4°C. Follow ing two rinses with TB containing 0.1% Triton-X and once in TB, the sections were incubated with biotinylated goat antirabbit IgG (Vector Laboratories, Burlingame, CA) in TBS, 1:100 dilution, for 30 min at room temperature. After two rinses with TB containing 0.1% Triton-X, the sections were incubated with an avidin/biotin/peroxidase complex (Vector Laboratories) for 30 min at room temperature. Three rinses in TB were then followed by a 3-5 min reaction with diaminobenzadine solution (5 mg diaminobenzadine tetrahydrocholoride, 68 mg imidazole, and 7 mg of NaNa in 10 ml of TB), to which 100 | JL1 of 0.0015% H2O2 was added. Peroxidase immunohistochemistry with antibodies to glial fibrillary acidic protein was used to evaluate reactive astrocytic gliosis.
Neuropathology
CNS, sciatic nerve and skeletal muscle pathologies were as sessed by standard procedures (Scott et al. 1989; Westaway et al. 1994) .
